| Original language | English |
|---|---|
| Pages (from-to) | 86-89 |
| Number of pages | 4 |
| Journal | Neurology |
| Volume | 74 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2010 Jan |
ASJC Scopus subject areas
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Discordant clinicopathologic phenotypes in a japanese kindred of fatal familial insomnia. / Saitoh, Y.; Ogawa, M.; Naito, Y.; Komatsuzaki, Y.; Tagaya, H.; Arima, K.; Tamaoka, A.; Kitamoto, T.; Murata, M.
In: Neurology, Vol. 74, No. 1, 01.2010, p. 86-89.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Discordant clinicopathologic phenotypes in a japanese kindred of fatal familial insomnia
AU - Saitoh, Y.
AU - Ogawa, M.
AU - Naito, Y.
AU - Komatsuzaki, Y.
AU - Tagaya, H.
AU - Arima, K.
AU - Tamaoka, A.
AU - Kitamoto, T.
AU - Murata, M.
N1 - Funding Information: Study funding: Supported by a grant from the Research Committee on Prion Diseases and Slow Virus Infection and Research Grant 19A-4 for Nervous and Mental Disorders, Ministry of Health, Labour, and Welfare, Japan. Funding Information: Disclosure: Dr. Saitoh and Dr. Ogawa report no disclosures. Dr. Naito has received research support from Asubio Pharmaceuticals, Inc., Janssen, Otsuka Pharmaceutical Co. Ltd., and Ono Pharmaceutical Co. Ltd. Dr. Komatsuzaki reports no disclosures. Dr. Tagaya received funding for travel from Sanofi-Aventis, serves on speakers' bureaus for Sanofi-Aventis, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, and KYORIN Pharmaceutical Co., Ltd., and receives research support from the Ministry of Health, Labour, and Welfare, Japan, Ministry of Education, Culture, Science and Technology, Japan, and Kitasato University School of Allied Health Sciences. Dr. Arima reports no disclosures. Dr. Tamaoka serves on a scientific advisory board for Chugai Pharmaceutical Company and has received research support from Sankyo Seimei, Ministry of Health, Labour, and Welfare, Japan, and Ministry of Education, Culture, Science and Technology, Japan. Dr. Kitamoto reports no disclosures. Dr. Murata serves on speakers' bureaus for Dainippon Sumitomo Pharma Co., Ltd., Novartis, Boehringer Ingelheim, and GlaxoSmithKline and receives research support from the Ministry of Health, Labour, and Welfare, Japan.
PY - 2010/1
Y1 - 2010/1
UR - http://www.scopus.com/inward/record.url?scp=74049132654&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74049132654&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e3181c7da09
DO - 10.1212/WNL.0b013e3181c7da09
M3 - Article
C2 - 20038778
AN - SCOPUS:74049132654
VL - 74
SP - 86
EP - 89
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 1
ER -